Opendata, web and dolomites

MYA

MYA, the innovative diagnostics platform for the full mapping of personal allergies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MYA project word cloud

Explore the words cloud of the MYA project. It provides you a very rough idea of what is the project "MYA" about.

laboratories    individuals    turn    proper    conveniently    incurred    cumulative    worldwide    mya    saturated    provision    primary    centres    agree    disease    website    plex    immune    array    market    personalized    detection    treatments    life    risk    relieve    weeks    million    advice    ige    chronic    map    quality    prescribe    days    accessible    food    allergy    serve    ship    ready    reducing    specialists    contact    full    units    personal    care    treatment    revenues    run    scarcity    extreme    quantitatively    suffering    limited    alltox    inadequate    profile    efficiency    screening    allergens    detect    price    entails    affordable    500    time    gets    either    pharmacies    420       network    international    made    diagnostic    population    created    allergen    launch    patients    patient    benefits    immunoglobulin    diagnosis    caused    self    allergies    report    collect    inhalant    healthcare    costly    150    public    saved    selling    society   

Project "MYA" data sheet

The following table provides information about the project.

Coordinator
ALLTOX S.R.L. 

Organization address
address: VIA SARDEGNA 38
city: MILANO
postcode: 20146
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.alltox.it/en/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2016-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ALLTOX S.R.L. IT (MILANO) coordinator 50˙000.00

Map

 Project objective

Allergies are chronic conditions caused by an extreme immune response to inhalant and food allergens that affect today 500 million (M) individuals worldwide and 150 M in Europe. International institutions all agree in the benefits that early allergy diagnosis and targeted treatment could bring to society. However, only 5% of the population gets a proper diagnosis, either due to limited awareness or scarcity of allergy specialists. Thus, patients try to self-manage their condition and non-specialists prescribe inadequate treatments. Therefore, the patient’s quality of life could be improved if allergy diagnosis were made accessible to the general public. Also, € 30 M/year would be saved in Europe by enhancing the efficiency of our healthcare system. In response, ALLTOX has created MYA (Map Your Allergies), a high quality, cost-effective test for allergy screening. Our 40-plex array-based technology will serve to quantitatively detect the patient’s immunoglobulin IgE, which are produced by the immune system upon contact with a particular allergen. The personal allergy profile can be obtained and thus, facilitate an adequate management. MYA will be offered to the general public at an affordable price through a network of pharmacies and primary care centres, who will collect the sample and ship it to our selected laboratories to run the analysis. In only 3 days, a full report and personalized advice will be conveniently available to the patient through our website, greatly reducing the current time-to-diagnosis (8 weeks). Our product entails a cost-effective diagnostic test that will facilitate detection of allergy risk and provision of adequate management to those patients suffering from this chronic disease. Also, the MYA test will help to relieve the costly impact incurred by allergies on our ready saturated healthcare system. In turn, MYA will provide ALLTOX estimated cumulative revenues of €40.2 M after selling 420 000 units within five years from market launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MYA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MYA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

FURTHER (2019)

Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients with Bone Metastasis

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More